Trials / Conditions / Graves Orbitopathy

Graves Orbitopathy

11 registered clinical trials studyying Graves Orbitopathy — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Completed	A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease NCT06226545	Lassen Therapeutics Inc.	Phase 2
Not Yet Recruiting	A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 S NCT05049603	University of Pisa	Phase 3
Recruiting	Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TE NCT06112340	Sling Therapeutics, Inc.	Phase 2 / Phase 3
Active Not Recruiting	Development of a Non-Invasive Prognostic Test for Graves Orbitopathy NCT07472062	University Hospital, Ghent	N/A
Unknown	A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy NCT04776993	University of Pisa	Phase 3
Active Not Recruiting	A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) NCT05276063	Sling Therapeutics, Inc.	Phase 2 / Phase 3
Terminated	A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) NCT04737330	Novartis Pharmaceuticals	Phase 3
Completed	Immunological Follow-up of Patients With Basedow's Orbitopathy NCT04610723	University Hospital, Montpellier	—
Unknown	Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy NCT05199103	Medical University of Silesia	N/A
Completed	Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Ra NCT03298867	Amgen	Phase 3
Approved For Marketing	Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease NCT04040894	Amgen	—